ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 16,809 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 16,809 shares of the business’s stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $65.17, for a total transaction of $1,095,442.53. Following the transaction, the chief operating officer now owns 782,620 shares in the company, valued at approximately $51,003,345.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $65.40, for a total value of $622,608.00.
• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $65.62 on Tuesday. ANI Pharmaceuticals, Inc. has a 12 month low of $36.99 and a 12 month high of $70.81. The business’s fifty day simple moving average is $65.12 and its two-hundred day simple moving average is $58.70. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 78.12 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The company had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ANIP. State of Alaska Department of Revenue lifted its position in ANI Pharmaceuticals by 8.9% during the third quarter. State of Alaska Department of Revenue now owns 9,975 shares of the specialty pharmaceutical company’s stock valued at $579,000 after purchasing an additional 813 shares during the period. Robeco Institutional Asset Management B.V. purchased a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $189,000. Maryland State Retirement & Pension System lifted its holdings in shares of ANI Pharmaceuticals by 8.8% during the 3rd quarter. Maryland State Retirement & Pension System now owns 5,901 shares of the specialty pharmaceutical company’s stock valued at $343,000 after buying an additional 476 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of ANI Pharmaceuticals by 9.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 123,717 shares of the specialty pharmaceutical company’s stock worth $7,183,000 after buying an additional 10,234 shares during the last quarter. Finally, New York State Teachers Retirement System grew its holdings in shares of ANI Pharmaceuticals by 0.9% in the third quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after acquiring an additional 200 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of recent research reports. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. HC Wainwright raised their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Truist Financial increased their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.